SLC5A2 and atherosclerosis: As nonspecialists, PCPs may be more reliant on guideline decision trees [38], which present the selection of GLP-1 RAs and SGLT2 inhibitors as an “either/or” treatment choice for patients with or at high risk for atherosclerotic CVD (ASCVD).